China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
MENLO PARK, Calif., Nov. 15, 2016 -- Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the fourth quarter and fiscal year (FY) ended September 30, 2016 on Monday, November 21, 2016 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and report on recent progress.
Conference Call and Webcast Details
Investors and analysts can access the call toll-free by dialing (844) 831-3024 (United States) or +1 (315) 625-6887 (international). The conference ID# is 17537774. The conference call also will be available via a live audio webcast which may be accessed here, or by visiting “Events & Presentations” in the Investors section of the Company’s website at www.coriumgroup.com. The webcast will be archived on the Corium website for two weeks following the presentation.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma, Endo Pharmaceuticals and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that has recently completed Phase 3 trials, and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumgroup.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Investor and Media Contact: SMP Communications Susan Pietropaolo [email protected] (201) 923-2049
